<DOC>
	<DOCNO>NCT00891046</DOCNO>
	<brief_summary>This open-label extension study permit patient Systemic Juvenile Idiopathic Arthritis ( SJIA ) previously responsive treatment canakinumab canakinumab treatment-naïve patient active SJIA without fever retreat 4 mg/kg s.c. every 4 week assess continued efficacy safety discontinuation study CACZ885G2402 place study center around March 2013 , whichever occur first . Patients steroid-free able taper canakinumab dose 2 mg/kg s.c. every 4 week .</brief_summary>
	<brief_title>An Open-label Extension Study Canakinumab Patients With Systemic Juvenile Idiopathic Arthritis Active Systemic Manifestations Manifestations Response Characterization Study Canakinumab Treatment-naïve Patients With Active SJIA With Without Fever .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Patients study CACZ885G2305 CACZ885G2301 achieve adapted ACR pediatric 30 response 15 day initial dose canakinumab clinically deteriorate afterwards minimum ACR Pediatric 30 response maintain Day 15 intervention deem necessary investigator , Patients study CACZ885G2301 eligible enter Part II ( withdrawal part ) able meet corticosteroid entry criterion , Responder patient Part I Part II flare CACZ885G2301 stop , CACZ885G2301 patient responder Part I experience flare Part II . Treatmentnaïve patient need meet following criterion : Confirmed diagnosis systemic juvenile idiopathic arthritis per ILAR definition must occur least 2 month prior enrollment onset disease &lt; 16 year age Male female patient age ≥ 2 &lt; 20 year age Active disease time enrollment define 2 following : Documented spiking , intermittent fever ( body temperature &gt; 38°C ) least 1 day screen period within 1 week first canakinumab dose At least 2 joint active arthritis AND Creactive protein ( CRP ) &gt; 30 mg/L ( normal range &lt; 10 mg/L ) Rash Serositis Lymphadenopathy Hepatosplenomegaly Naïve canakinumab Other protocoldefined inclusion criterion may apply Exclusion criterion : History allergy hypersensitivity study drug With active recurrent bacterial , fungal viral infection time enrollment Other protocol inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Flare</keyword>
	<keyword>arthritis</keyword>
	<keyword>IL-1beta antagonist</keyword>
	<keyword>systemic juvenile idiopathic arthritis</keyword>
	<keyword>CHAQ</keyword>
	<keyword>steroid</keyword>
	<keyword>ACR pediatric response</keyword>
	<keyword>Systemic juvenile idiopathic arthritis active flare</keyword>
</DOC>